High risk pregnancy. Supervision of high risk pregnancy
Conditions
Interventions
Intervention 1: Intervention group: In this group
Treatment with oral aspirin tablets (Cardiosprin 80 grams, manufactured by Samisaz, Iran) on a daily basis from the 12th week of pregnancy to the 36th week
Together with vaginal progesterone suppositories (Cyclogest 400 mg, manufactured by Octoverco, Iran) daily from the 12th week of pregnancy to the 34th week. Intervention 2: Control group: In this grou
Treatment with oral aspirin tablets (Cardiopirin 80 grams, manufactured by Samisaz Company, Iran) is performed daily from the 12th week of pregnancy to the 36th week.
Sponsors
Semnan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 and above Body mass index above 30 The interval between pregnancies is more than 10 years Multiple pregnancy Pre-gestational diabetes Live singleton fetus
Exclusion criteria
Exclusion criteria: Heart, liver, thyroid diseases, history of asthma Aspirin sensitivity Threatened abortion such as vaginal bleeding Eclampsia and pre-eclampsia at the time of study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vascular Resistance Index (RI). Timepoint: Before the intervention and 6 weeks after the intervention. Method of measurement: Color Doppler ultrasound.;Pulsatile index (PI). Timepoint: Before the intervention and 6 weeks after the intervention. Method of measurement: Color Doppler ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSatinik Darzi
Semnan University of Medical Sciences
Outcome results
None listed